CASI Pharmaceuticals - CASI Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month target prices for CASI Pharmaceuticals' shares. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 402.5% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.

CASI Pharmaceuticals' stock was trading at $1.79 on January 1st, 2023. Since then, CASI shares have increased by 11.2% and is now trading at $1.99.
View the best growth stocks for 2023 here.

CASI Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 277,800 shares, a decrease of 5.9% from the December 31st total of 295,200 shares. Based on an average daily volume of 33,900 shares, the short-interest ratio is currently 8.2 days. Approximately 2.1% of the company's shares are sold short.
View CASI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CASI earnings forecast.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Monday, November, 14th. The biotechnology company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.13. The biotechnology company had revenue of $10.21 million for the quarter, compared to analyst estimates of $10.40 million. CASI Pharmaceuticals had a negative net margin of 73.17% and a negative trailing twelve-month return on equity of 37.59%.

Shares of CASI Pharmaceuticals reverse split on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CASI stock can currently be purchased for approximately $1.99.

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $27.08 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

The company employs 176 workers across the globe.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.